{
    "clinical_study": {
        "@rank": "99270", 
        "arm_group": [
            {
                "arm_group_label": "Oxytocin", 
                "arm_group_type": "Experimental", 
                "description": "A single 100 microgram IV dose of carbetocin after operation"
            }, 
            {
                "arm_group_label": "Carbetocin", 
                "arm_group_type": "Experimental", 
                "description": "A standard 30 international units (IU) IV infusion of oxytocin during two hours"
            }
        ], 
        "brief_summary": {
            "textblock": "Postpartum hemorrhage (PPH) is a common complication of childbirth and a leading cause of\n      maternal morbidity and mortality. The prompt and effective treatment of subjects with PPH\n      would reduce operation risks. Hence in this study, the efficacy of Oxytocin and Carbetocin\n      was compared in prevention of postpartum hemorrhage after cesarean sections."
        }, 
        "brief_title": "Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Postpartum Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Postpartum Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least one risk for postpartum hemorrhage and lack of hypersensitivity to oxytocin\n             and carbetocin\n\n        Exclusion Criteria:\n\n          -  Patients' refusal to cooperate, major therapeutic side effects, history of cardiac\n             and renal disease or preeclampsia"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079558", 
            "org_study_id": "IRHRC-021", 
            "secondary_id": "JANU2014TAHERIPANAH"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carbetocin", 
                "description": "Carbetocin with single 100 microg IV dosage was used in this investigation", 
                "intervention_name": "Carbetocin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Duratocin,", 
                    "Pabal,", 
                    "Lonactene"
                ]
            }, 
            {
                "arm_group_label": "Oxytocin", 
                "description": "Oxytocin with 30 international units (IU) IV infusion was used in this investigation", 
                "intervention_name": "Oxytocin", 
                "intervention_type": "Drug", 
                "other_name": "Pitocin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxytocin", 
                "Carbetocin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "prevention", 
            "cesarean section"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "1985717443"
                }, 
                "name": "Infertility and Reproductive Health Research Center"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section", 
        "overall_official": {
            "affiliation": "Infertility and Reproductive health Research center, Imam Hossien hospital, Shahid Beheshti Medical university, Tehran, Iran", 
            "last_name": "Robabeh Taheripanah, MD-Gyn.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "screening of Cessation of bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "screening until 24 hours after placenta disconnection"
            }, 
            {
                "measure": "time duration to stop bleeding in the case of post-cesarean section", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079558"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shahid Beheshti Medical University", 
            "investigator_full_name": "Dr Robabeh Taheripanah", 
            "investigator_title": "Associated prof. Obstetrics & Gynecology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}